Adalimumab is now recommended as a treatment option for people with severe, active Crohn's disease.
Infliximab continues to be recommended for adults with active, fistulising disease, and for adults and children from the age of 6 years with severe, active disease. However, NICE now advises that infliximab should be given in a planned course until treatment failure, or for up to 12 months if sooner. Continued treatment is indicated only if there is clear evidence of ongoing active disease.
Use of both adalimumab and infliximab is restricted to patients who have failed to respond to, are intolerant of, or are unable to take more commonly used treatment options. Treatment should normally be started with the less expensive agent.